Summary
Shortening of telomeres prevents cells from uncontrolled proliferation. Progressive telomere shortening occurs at each cell division until a critical telomeric length is reached. Telomerase expression is switched off after embryonic differentiation in most normal cells, but it is expressed in a very high percentage of tumors of different origin. Thus, telomerase is regarded as the best tumor marker and a promising novel molecular target for cancer treatment. Therefore, different strategies to inhibit telomerase have been developed. However, systematic screening of telomerase inhibitors has not been performed to compare their therapeutic potential. We propose a suitable strategy for estimation of the therapeutic potential of telomerase inhibitors, which is based on a systematic screening of different inhibitors in the same cell system. From the long list of compounds discussed in the literature, we have selected four telomerase inhibitors of different structure and mode of action: BRACO19 (G-quadruplex-interactive compound), BIBR1532 (non-nucleosidic reverse transcriptase inhibitor), 2′-O-methyl RNA, and peptide nucleic acids (PNAs; hTR antisense oligonucleotides). To determine minimal effective concentrations for telomerase inhibition, telomerase activity was measured using the cell-free telomerase repeat amplification protocol (TRAP) assay. We also tested inhibitors in long-term cell-culture experiments by exposing A-549 cells to non-cytotoxic concentrations of inhibitors for a period of 99 days. Subsequently, telomerase activity of A-549 cells was investigated using the TRAP assay, and telomere length of samples was assessed by telomere restriction fragment (TRF) Southern blot analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Janknecht, R. (2004) On the road to immortality: hTERT upregulation in cancer cells, FEBS Lett. 564, 9–13.
Nakajima, A., Tauchi, T., Sashida, G., Sumi, M., Abe, K., Yamamoto, K., Ohyashiki, J. H., and Ohyashiki, K. (2003) Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy, Leukemia 17, 560–567.
Shammas, M. A., Shmookler Reis, R. J., Li, C., Koley, H., Hurley, L. H., Anderson, K. C., and Munshi, N. C. (2004) Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma, Clin. Cancer Res. 10, 770–776.
Shammas, M. A., Koley, H., Batchu, R. B., Bertheau, R. C., Protopopov, A., Munshi, N. C., and Goyal, R. K. (2005) Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett’s adenocarcinoma cells: mechanism and therapeutic potential, Mol. Cancer 4, 24.
Norton, J. C., Piatyszek, M. A., Wright, W. E., Shay, J. W., and Corey, D. R. (1996) Inhibition of human telomerase activity by peptide nucleic acids, Nat. Biotechnol. 14, 615–619.
Pitts, A. E. and Corey, D. R. (1998) Inhibition of human telomerase by 2′-O-methyl-RNA, Proc. Natl. Acad. Sci. U. S. A. 95, 11549–11554.
Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U. M., Wenz, C., Lingner, J., Kraut, N., Rettig, W. J., and Schnapp, A. (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation, EMBO J. 20, 6958–6968.
Gowan, S. M., Harrison, J. R., Patterson, L., Valenti, M., Read, M. A., Neidle, S., and Kelland, L. R. (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity, Mol. Pharmacol. 61, 1154–1162.
Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. (1999) Cancer statistics, 1999, CA Cancer J. Clin. 49, 8–31.
Hsu, C. P., Miaw, J., Hsia, J. Y., Shai, S. E., and Chen, C. Y. (2003) Concordant expression of the telomerase-associated genes in non-small cell lung cancer, Eur. J. Surg. Oncol. 29, 594–599.
Dikmen, E., Kara, M., Dikmen, G., Cakmak, H., and Dogan, P. (2003) Detection of telomerase activity in bronchial lavage as an adjunct to cytological diagnosis in lung cancer, Eur. J. Cardiothorac. Surg. 23, 194–199.
Albanell, J., Lonardo, F., Rusch, V., Engelhardt, M., Langenfeld, J., Han, W., Klimstra, D., Venkatraman, E., Moore, M. A., and Dmitrovsky, E. (1997) High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage, J. Natl. Cancer Inst. 89, 1609–1615.
Piotrowska, K., Kleideiter, E., Mürdter, T. E., Tätz, S., Baldes, C., Schäfer, U., Lehr, C.-M., and Klotz, U. (2005) Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Lab. Invest. 85, 1565–1569.
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. (1994) Specific association of human telomerase activity with immortal cells and cancer, Science 266, 2011–2015.
Acknowledgments
We thank Jessica Lauser for her excellent technical assistance. Tumor material was kindly provided by Dr G. Friedel from the Department of Thorax Surgery, Schillerhöhe Clinical Center, Gerlingen, Germany, and Dr P. Fritz from Robert Bosch Hospital in Stuttgart, Germany. The project is financially supported by German Cancer Aid, Bonn, Germany, and Robert Bosch Foundation, Stuttgart, Germany.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this protocol
Cite this protocol
Kleideiter, E., Piotrowska, K., Klotz, U. (2007). Screening of Telomerase Inhibitors. In: Andrews, L.G., Tollefsbol, T.O. (eds) Telomerase Inhibition. Methods in Molecular Biology™, vol 405. Humana Press. https://doi.org/10.1007/978-1-60327-070-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-60327-070-0_13
Publisher Name: Humana Press
Print ISBN: 978-1-58829-683-2
Online ISBN: 978-1-60327-070-0
eBook Packages: Springer Protocols